Our Latest News - BUHLMANN

BUHLMANN News

BÜHLMANN GanglioCombi™ MAG ELISA Utilized in Guillain-Barré Syndrome (GBS) and Zika Virus Study

The BÜHLMANN GanglioCombi™ MAG ELISA was recently utilized in a case-control study in French Polynesia focusing on individuals diagnosed with Guillain-Barré Syndrome (GBS). See publication below: Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study Learn More BÜHLMANN GanglioCombi® MAG ELISA is for Research Use Only. Not for use in diagnostic procedures in
Continue Reading

Connect with BUHLMANN Diagnostics Corp at MGCC 2016!

When: June 18 - 22, 2016 Where: Edmonton, AB Canada Booth: #307   More Information: Joint Conference of the Canadian College of Medical Geneticists and the Canadian Society of Clinical Chemists (MGCC 2016)
Continue Reading

Testing Potency and Efficacy of Inhibitors of P13K, SYK, BTK Activity

The Flow CAST® is intended for the determination of basophil activation in whole blood samples by flow cytometry. Our unique marker combination – CCR3 and CD63 – combines the simple gating properties for basophil detection by CCR3 with the solid application of the proven activation marker CD63 in one. Thanks to its easy protocol and smart
Continue Reading

New Health Canada License for BÜHLMANN fCAL® turbo

BÜHLMANN fCAL® turbo Speed, Quality and Flexibility in Calprotectin Quantification BUHLMANN Diagnostics Corp (BDC), BÜHLMANN Laboratories AG’s North American affiliate is proud to announce that its innovative product, BÜHLMANN fCAL® turbo, has received a Medical Device License from Health Canada and is now commercially available in Canada.  The device was approved as a Class 2
Continue Reading

Connect with BUHLMANN Diagnostics Corp (BDC) at DDW 2016

When: May 21-24, 2016 Where: San Diego, California Booth: #4155 More Information: Digestive Disease Week (DDW) 2016
Continue Reading

Calprotectin Video from Canadian Digestive Health Foundation (CDHF)

The Canadian Digestive Health Foundation (CDHF) has recently produced a very interesting video about the use of calprotectin to confirm and predict flares in inflammatory bowel disease patients and how it can be used to manage IBD.

Continue Reading

Connect with BUHLMANN Diagnostics Corp at CDDW 2016

When: February 26 - 29, 2016 Where: Montreal, Quebec, Canada - Fairmont Queen Elizabeth Hotel' Booth: #1050 More Information Canadian Digestive Diseases Week
Continue Reading

Random Access Immuno Turbidimetric Faecal Calprotectin Assay

In autumn 2015 BÜHLMANN will launch a new generation of faecal calprotectin assay. The BÜHLMANN fCAL™turbo, the next step in automation of faecal calprotectin quantification used for Research Use Only. Fecal calprotectin (fCAL) is the most important marker in the study of gut inflammation. fCAL testing today demands for a raised level of lab resources including

Continue Reading

Market Launch Of CALEX Device

  BÜHLMANN announces the launch and introduction of the brand new stool extraction device CALEX® Cap. The features of the CALEX® extraction tool are unique in the market: Ease of use for laboratory personnel and subjects Application as primary tube for all ELISA robots on the market An optimized sample dilution for maximum efficiency in

Continue Reading